Literature DB >> 30686716

Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women.

Min-Sun Kwak1, Jeong Yoon Yim2, Ann Yi3, Goh-Eun Chung4, Jong In Yang5, Donghee Kim6, Joo Sung Kim7, Dong-Young Noh8.   

Abstract

BACKGROUND: Growing evidence supports that nonalcoholic fatty liver disease (NAFLD) is associated with extrahepatic cancers. Nonalcoholic fatty liver disease (NAFLD) and breast cancer share similar risk factors, including obesity. AIM: The aim of this case-control study was to investigate the association between NAFLD and breast cancer.
METHODS: Subjects who received health screening, including mammography and breast and hepatic ultrasonography simultaneously, were included. Subjects diagnosed with breast cancer were matched with controls. Conditional logistic regression analyses were performed.
RESULTS: Among 270 breast cancer patients and 270 controls, 81 cancer patients (30.0%) and 54 controls (20.0%) had NAFLD (P = 0.008). NAFLD was significantly associated with breast cancer in multivariate analysis (P = 0.046). When the interaction between obesity (BMI < 25 kg/m2 vs. ≥25 kg/m2) and NAFLD in breast cancer patients was examined, a significant effect modification between obesity and NAFLD in breast cancer was noted (P = 0.021). The subgroup analysis showed that NAFLD was significantly associated with breast cancer in the nonobese subgroup (odds ratio 3.04, 95% confidence interval 1.37-4.32, P = 0.002) but not in the obese group (P = 0.163).
CONCLUSIONS: NAFLD was significantly associated with breast cancer independent of traditional risk factors, and this association existed in the nonobese subgroup but not in the obese subgroup.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Breast cancer; Fatty liver; Hepatic steatosis; Obesity

Mesh:

Year:  2019        PMID: 30686716     DOI: 10.1016/j.dld.2018.12.024

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  12 in total

Review 1.  Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer.

Authors:  Kara Wegermann; Jeongeun Hyun; Anna Mae Diehl
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 2.  Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 3.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 4.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

5.  Tamoxifen induces fatty liver disease in breast cancer through the MAPK8/FoxO pathway.

Authors:  Liuyun Gong; Hanmin Tang; Zhenzhen Luo; Xiao Sun; Xinyue Tan; Lina Xie; Yutiantian Lei; Mengjiao Cai; Chenchen He; Jinlu Ma; Suxia Han
Journal:  Clin Transl Med       Date:  2020-04-23

Review 6.  Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.

Authors:  Amedeo Lonardo; Ayako Suzuki
Journal:  J Clin Med       Date:  2020-04-28       Impact factor: 4.241

7.  Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis.

Authors:  Shou-Sheng Liu; Xue-Feng Ma; Jie Zhao; Shui-Xian Du; Jie Zhang; Meng-Zhen Dong; Yong-Ning Xin
Journal:  Lipids Health Dis       Date:  2020-05-31       Impact factor: 3.876

8.  The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers.

Authors:  Nicolette Veracruz; Bilal Hameed; Sammy Saab; Robert J Wong
Journal:  J Clin Exp Hepatol       Date:  2020-05-20

9.  A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.

Authors:  Fatemeh Haidari; Abdollah Hojhabrimanesh; Bizhan Helli; Seyed-Saeed Seyedian; Kambiz Ahmadi-Angali; Behnaz Abiri
Journal:  BMC Gastroenterol       Date:  2020-10-20       Impact factor: 3.067

10.  The Possible Association of Non-Alcoholic Fatty Liver Disease with Acute Cholangitis: A Retrospective Multicenter Cohort Study.

Authors:  Wisam Sbeit; Moeen Sbeit; Itay Kalisky; Lior Katz; Amir Mari; Tawfik Khoury
Journal:  Life (Basel)       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.